Jun. 24 at 12:23 PM
$CTMX Let’s not forget “Regeneron has expanded its research alliance with CytomX Therapeutics, paying
$37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The expansion swells the potential value of the deal to about
$4 billion.
CytomX partnered with Regeneron in 2022. Back then, Regeneron paid
$30 million upfront to develop candidates based on its bispecific antibody development platform and CytomX’s technology for keeping molecules inactive until they reach the tumor microenvironment. The deal featured up to
$800 million in milestones, plus up to
$1.2 billion in further paydays tied to expanding the collaboration. ”
